TWI792596B - 新穎脂肪酸及其於共軛至生物分子之用途 - Google Patents

新穎脂肪酸及其於共軛至生物分子之用途 Download PDF

Info

Publication number
TWI792596B
TWI792596B TW110136772A TW110136772A TWI792596B TW I792596 B TWI792596 B TW I792596B TW 110136772 A TW110136772 A TW 110136772A TW 110136772 A TW110136772 A TW 110136772A TW I792596 B TWI792596 B TW I792596B
Authority
TW
Taiwan
Prior art keywords
conjugate
mmol
peptide
acid
gdf15
Prior art date
Application number
TW110136772A
Other languages
English (en)
Chinese (zh)
Other versions
TW202204384A (zh
Inventor
大衛 溫英傑 伯尼斯
山田健
去克溫杜 伊比邦久
阿洛克許 都塔羅伊
路易斯 克萊爾 可曼
亞立山卓 馬歇爾 布魯斯
愛咪 瑞察德森 優瑟拉
佛瑞德利克 查克利
強 元
樓長剛
艾倫 肯特
愛薇洛普 博斯
Original Assignee
瑞士商諾華公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53491695&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TWI792596(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 瑞士商諾華公司 filed Critical 瑞士商諾華公司
Publication of TW202204384A publication Critical patent/TW202204384A/zh
Application granted granted Critical
Publication of TWI792596B publication Critical patent/TWI792596B/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2221—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/22—Tricarboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/18—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon triple bonds as unsaturation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/285—Polyhydroxy dicarboxylic acids having five or more carbon atoms, e.g. saccharic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
TW110136772A 2014-06-23 2015-06-22 新穎脂肪酸及其於共軛至生物分子之用途 TWI792596B (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201462015862P 2014-06-23 2014-06-23
US62/015,862 2014-06-23
US201462082327P 2014-11-20 2014-11-20
US62/082,327 2014-11-20
US201562107016P 2015-01-23 2015-01-23
US62/107,016 2015-01-23

Publications (2)

Publication Number Publication Date
TW202204384A TW202204384A (zh) 2022-02-01
TWI792596B true TWI792596B (zh) 2023-02-11

Family

ID=53491695

Family Applications (3)

Application Number Title Priority Date Filing Date
TW109123095A TWI750725B (zh) 2014-06-23 2015-06-22 新穎脂肪酸及其於共軛至生物分子之用途
TW110136772A TWI792596B (zh) 2014-06-23 2015-06-22 新穎脂肪酸及其於共軛至生物分子之用途
TW104120074A TWI701048B (zh) 2014-06-23 2015-06-22 新穎脂肪酸及其於共軛至生物分子之用途

Family Applications Before (1)

Application Number Title Priority Date Filing Date
TW109123095A TWI750725B (zh) 2014-06-23 2015-06-22 新穎脂肪酸及其於共軛至生物分子之用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW104120074A TWI701048B (zh) 2014-06-23 2015-06-22 新穎脂肪酸及其於共軛至生物分子之用途

Country Status (37)

Country Link
US (4) US10588980B2 (fr)
EP (2) EP3988170A1 (fr)
JP (5) JP6636959B2 (fr)
KR (2) KR102559975B1 (fr)
CN (3) CN107073130B (fr)
AP (1) AP2016009585A0 (fr)
AU (1) AU2015280351C1 (fr)
CA (1) CA2953480A1 (fr)
CL (1) CL2016003281A1 (fr)
CR (1) CR20160596A (fr)
CU (1) CU24455B1 (fr)
CY (1) CY1125006T1 (fr)
DK (1) DK3157571T3 (fr)
EA (1) EA039074B1 (fr)
EC (1) ECSP17004665A (fr)
ES (1) ES2905479T3 (fr)
GT (1) GT201600263A (fr)
HK (1) HK1232160A1 (fr)
HR (1) HRP20220152T1 (fr)
HU (1) HUE057845T2 (fr)
IL (1) IL248990B (fr)
JO (1) JO3813B1 (fr)
LT (1) LT3157571T (fr)
MA (1) MA40278A (fr)
MX (1) MX367520B (fr)
MY (1) MY193993A (fr)
PE (1) PE20171095A1 (fr)
PH (1) PH12016502294B1 (fr)
PL (1) PL3157571T3 (fr)
PT (1) PT3157571T (fr)
RS (1) RS62907B1 (fr)
SG (2) SG10201912965TA (fr)
SI (1) SI3157571T1 (fr)
TN (1) TN2016000558A1 (fr)
TW (3) TWI750725B (fr)
UY (1) UY36186A (fr)
WO (1) WO2015200078A1 (fr)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200936156A (en) 2008-01-28 2009-09-01 Novartis Ag Methods and compositions using Klotho-FGF fusion polypeptides
US8420088B2 (en) 2008-01-28 2013-04-16 Novartis Ag Methods and compositions using FGF23 fusion polypeptides
JP5977814B2 (ja) 2011-04-08 2016-08-24 アムジエン・インコーポレーテツド 増殖分化因子１５（ｇｄｆ−１５）を使用して代謝障害を治療または改善する方法
NZ754961A (en) 2013-07-31 2022-04-29 Amgen Inc Growth differentiation factor 15 (gdf-15) constructs
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
WO2016088059A1 (fr) 2014-12-04 2016-06-09 Novartis Ag Procédés et compositions employant des polypeptides variants de klotho
EA201791668A1 (ru) * 2015-01-23 2017-11-30 Новартис Аг Синтетические конъюгаты апелина с жирной кислотой с улучшенным периодом полураспада
CN108367053A (zh) * 2015-12-22 2018-08-03 诺华股份有限公司 使用生长分化因子15(gdf-15)治疗或改善代谢性疾病的方法
AU2017210726B2 (en) 2016-01-31 2023-08-03 University Of Massachusetts Branched oligonucleotides
BR112018072034A2 (pt) 2016-05-24 2019-02-12 Novo Nordisk A/S compostos mic-1 e usos dos mesmos
KR101727506B1 (ko) * 2016-07-14 2017-05-04 충남대학교 산학협력단 Gdf15 단백질 또는 이를 암호화하는 폴리뉴클레오티드를 유효성분으로 함유하는 지방간의 예방 또는 치료용 약학적 조성물
CA3033368A1 (fr) * 2016-08-12 2018-02-15 University Of Massachusetts Oligonucleotides conjugues
KR102619197B1 (ko) 2017-01-23 2024-01-03 리제너론 파마슈티칼스 인코포레이티드 Hsd17b13 변종 및 이것의 용도
CN110637027A (zh) 2017-02-08 2019-12-31 百时美施贵宝公司 包含药代动力学增强子的修饰的松弛素多肽及其用途
AU2018250727A1 (en) 2017-04-11 2019-10-31 Regeneron Pharmaceuticals, Inc. Assays for screening activity of modulators of members of the hydroxysteroid (17-beta) dehydrogenase (HSD17B) family
JP2020520926A (ja) * 2017-05-18 2020-07-16 レゲネロン ファーマシューティカルス，インコーポレーテッド ビス−オクタヒドロフェナントレンカルボキサミド及びそのタンパク質コンジュゲート
TWI710377B (zh) * 2017-05-23 2020-11-21 丹麥商諾佛 儂迪克股份有限公司 Ｍｉｃ－１化合物及其用途
EP3695012B1 (fr) 2017-10-11 2023-03-08 Regeneron Pharmaceuticals, Inc. Inhibition de hsd17b13 dans le traitement de la maladie hépatique chez des patients exprimant la variation pnpla3 i148m
TWI811280B (zh) * 2017-12-22 2023-08-11 瑞士商諾華公司 用fgf21變體治療代謝障礙之方法
WO2019179494A1 (fr) * 2018-03-23 2019-09-26 深圳市塔吉瑞生物医药有限公司 Composé d'acide pentadécanedioïque substitué, composition pharmaceutique et utilisation associée
MX2020010659A (es) 2018-04-09 2020-10-28 Amgen Inc Proteinas de fusion del factor de diferenciacion de crecimiento 15.
BR112020024351A2 (pt) 2018-06-01 2021-02-23 Novartis Ag moléculas de ligação contra bcma e usos das mesmas
SG11202101288TA (en) 2018-08-10 2021-03-30 Univ Massachusetts Modified oligonucleotides targeting snps
KR20210044244A (ko) 2018-08-10 2021-04-22 노파르티스 아게 Gfral 세포외 도메인 및 사용 방법
TW202023573A (zh) * 2018-09-19 2020-07-01 美商Ionis製藥公司 Pnpla3表現之調節劑
US11713345B2 (en) * 2018-10-22 2023-08-01 Janssen Sciences Ireland Unlimited Company Glucagon like peptide 1 (GLP1)-growth differentiation factor 15 (GDF15) fusion proteins and uses thereof
CN113396158A (zh) 2018-11-26 2021-09-14 诺华股份有限公司 Lpl-gpihbp1融合多肽
MX2021012964A (es) * 2019-04-23 2021-12-10 Lg Chemical Ltd Polipeptido de fusion que comprende region fc de inmunoglobulina y gdf15.
CN111909256A (zh) * 2019-05-10 2020-11-10 宁波鲲鹏生物科技有限公司 多肽衍生物及其制备方法
CU20210096A7 (es) 2019-05-21 2022-06-06 Novartis Ag Moléculas de unión a cd19
US20230071196A1 (en) 2019-05-21 2023-03-09 Novartis Ag Variant cd58 domains and uses thereof
EP3999103A4 (fr) * 2019-07-19 2023-11-22 Inari Agriculture Technology, Inc. Édition génomique pour réparation dirigée par homologie améliorée
WO2021067655A1 (fr) 2019-10-04 2021-04-08 Amgen Inc. Utilisation de gdf15 pour le traitement d'un syndrome cardiométabolique et d'autres affections
EP4054521A1 (fr) 2019-11-04 2022-09-14 Ferring B.V. Administration intranasale de mérotocine pour améliorer la lactation
CA3161669A1 (fr) * 2019-11-26 2021-06-03 Dtx Pharma, Inc. Composes comprenant un acide nucleique et methodes
WO2021126990A1 (fr) * 2019-12-16 2021-06-24 The Scripps Research Institute Dérivés d'ocytocine ayant des propriétés améliorées
CN115260313B (zh) 2019-12-31 2023-07-18 北京质肽生物医药科技有限公司 Glp-1和gdf15的融合蛋白以及其缀合物
EP4090377A1 (fr) * 2020-01-13 2022-11-23 Synaffix B.V. Conjugués d'anticorps et d'agents de mise en contact de cellules immunitaires
WO2021144314A1 (fr) * 2020-01-13 2021-07-22 Synaffix B.V. Anticorps fonctionnalisés bilatéralement par cycloaddition
WO2021144313A1 (fr) * 2020-01-13 2021-07-22 Synaffix B.V. Anticorps fonctionnalisés bilatéralement par cycloaddition
KR20230104651A (ko) 2020-11-06 2023-07-10 노파르티스 아게 Cd19 결합 분자 및 이의 용도
KR102543789B1 (ko) * 2021-03-08 2023-06-20 주식회사 온코크로스 토르세미드 및 크로몰린을 포함하는 대사질환 예방 또는 치료용 조성물
WO2022219495A1 (fr) 2021-04-12 2022-10-20 Novartis Ag Dérivés de 2-((4-((s)-2-(4-chloro-2-fluorophényl)-2-méthylbenzo[d][1,3]dioxol-4-yl)pipéridin-1-yl)méthyl)-1-(((s)-oxétan-2-yl)méthyl)-1h-imidazole utilisés en tant qu'activateurs du récepteur glp1 pour le traitement de l'obésité
TW202304500A (zh) 2021-04-21 2023-02-01 瑞士商諾華公司 升糖素樣肽化合物
WO2022245183A1 (fr) * 2021-05-21 2022-11-24 Yuhan Corporation Composition pour la prévention ou le traitement d'une stéatose hépatique non alcoolique ou d'une stéatohépatite non alcoolique comprenant un variant de facteur de différenciation de croissance 15
CA3174095A1 (fr) 2021-06-23 2022-12-29 Vignesh Narayan HARIHARAN Composes oligonucleotidiques anti-flt1 optimises pour le traitement de la preeclampsie et d'autres troubles angiogeniques
WO2023039522A1 (fr) * 2021-09-10 2023-03-16 Guardian Therapeutics, Llc Conjugués acides gras d'acides nucléiques
CN113582832B (zh) * 2021-09-13 2024-01-26 深圳瑞德林生物技术有限公司 一种长链二酸的制备方法
WO2023152698A1 (fr) 2022-02-10 2023-08-17 Novartis Ag Dérivés de 2-((4-((s)-2-(4-chloro-2-fluorophényl)-2-méthylbenzo[d][1,3]dioxol-4-yl)pipéridin-1-yl)méthyl)-1-(((s)-oxétan-2-yl)méthyl)-1h-imidazole utilisés en tant qu'activateurs du récepteur glp1 pour le traitement de l'obésité
WO2023154953A1 (fr) 2022-02-14 2023-08-17 Ngm Biopharmaceuticals, Inc. Polypeptides gdf15 pour le traitement et la prévention de maladies auto-immunes
CN114740105B (zh) * 2022-03-17 2023-11-07 重庆医药高等专科学校 一种脯氨酸和n-甲基脯氨酸的液相色谱分离检测方法及其应用
WO2023196754A2 (fr) * 2022-04-08 2023-10-12 University Of North Texas Health Science Center At Fort Worth Traitement pour réduire ou prévenir une fibrose tissulaire
CN114891086B (zh) * 2022-06-01 2024-03-26 恺佧生物科技(上海)有限公司 一种生物素标记的gdf15的复性方法
WO2024030367A2 (fr) * 2022-08-01 2024-02-08 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Conjugués de peptides d'acides gras-d-acides aminés en tant que composés anaplérotiques destinés à être utilisés dans le traitement de l'acidémie propionique, de l'acidurias méthylmalonique et de troubles métaboliques de l'énergie
CN116466010B (zh) * 2023-06-15 2023-08-25 四川普锐特药业有限公司 一种用于脂质纳米粒中多种脂质组分定量检测的方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014083505A1 (fr) * 2012-11-30 2014-06-05 Novartis Ag Procédés pour la fabrication de conjugués à partir de protéines contenant du disulfure

Family Cites Families (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3043871A (en) * 1956-09-03 1962-07-10 Ruhrchemie Ag Production of heptadecanedicarboxylic acid-1, 17
GB2124618A (en) 1982-06-11 1984-02-22 Nat Res Dev Aliphatic hydroxy amides
US4517105A (en) 1983-03-07 1985-05-14 Aluminum Company Of America Metalworking lubricant composition containing a novel substituted malonic acid diester
US4582927A (en) 1984-04-04 1986-04-15 Frito-Lay, Inc. Synthetic cooking oils containing dicarboxylic acid esters
US5175191A (en) 1988-11-14 1992-12-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
EP0492628B1 (fr) 1990-12-26 1996-07-03 Ricoh Company, Ltd Composition colorante thermosensible et réversible, matériau d'enregistrement, méthode d'enregistrement et appareil pour l'affichage d'images utilisant le matériau d'enregistrement
US5994102A (en) 1994-12-15 1999-11-30 Human Genome Sciences, Inc. Polynucleotides encoding prostatic growth factor and process for producing prostatic growth factor polypeptides
AU1830195A (en) 1994-12-15 1996-07-03 Human Genome Sciences, Inc. Prostatic growth factor
US6521227B1 (en) 1999-11-18 2003-02-18 Peter L. Hudson Polynucleotides encoding prostatic growth factor and process for producing prostatic growth factor polypeptides
US6428771B1 (en) 1995-05-15 2002-08-06 Pharmaceutical Discovery Corporation Method for drug delivery to the pulmonary system
FR2735131B1 (fr) 1995-06-12 1997-08-22 Rech De Pathologie Appliquee S Conjugues d'msh avec un acide gras, leur procede de preparation et leur utilisation a titre de medicament
ATE423788T1 (de) 1995-06-22 2009-03-15 St Vincents Hosp Sydney Neues tgf-beta-ahnliches cytokin
US20020052310A1 (en) 1997-09-15 2002-05-02 Massachusetts Institute Of Technology The Penn State Research Foundation Particles for inhalation having sustained release properties
JP2001500732A (ja) 1996-09-11 2001-01-23 オーソ―マクニール・フアーマシユーチカル・インコーポレーテツド 前立腺がんを治療するためのＴＮＦ―β様タンパク質、ならびに関連する核酸分子、医薬組成物および方法
AU8591198A (en) 1997-07-31 1999-02-22 Johns Hopkins University School Of Medicine, The Growth differentiation factor-15
AU1685499A (en) 1997-12-24 1999-07-19 Takeda Chemical Industries Ltd. Polypeptide, their production and use
US6974684B2 (en) 2001-08-08 2005-12-13 Curagen Corporation Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US6297400B1 (en) 1999-07-02 2001-10-02 The Clorox Company Synthesis of a tetraamido macrocycle ligand from a novel diamidodiol
WO2001077288A2 (fr) 2000-04-06 2001-10-18 Genetics Institute, Llc. Polynucleotides codant pour de nouvelles proteines secretees
US7514221B2 (en) 2000-04-20 2009-04-07 St. Vincent's Hospital Sydney Limited Diagnostic assay and method of treatment involving macrophage inhibitory cytokine-1 (MIC-1)
DK1456360T3 (en) 2001-04-19 2015-08-31 Scripps Research Inst Methods and Composition for Preparation of Orthogonal TRNA-Aminoacyl-TRNA Synthetase Pairs
US20030166903A1 (en) 2001-04-27 2003-09-04 Anna Astromoff Genes associated with vascular disease
PT1441589E (pt) 2001-11-08 2012-08-13 Abbott Biotherapeutics Corp Formulação farmacêutica líquida estável de anticorpos igg
TW200303742A (en) 2001-11-21 2003-09-16 Novartis Ag Organic compounds
US7157235B2 (en) 2002-06-17 2007-01-02 St. Vincent's Hospital Sydney Limited Methods of diagnosis, prognosis and treatment of cardiovascular disease
BRPI0410779A (pt) 2003-05-20 2006-06-27 Novartis Ag heterociclos de n-acil nitrogênio como ligantes de receptores ativados por proliferador de peroxissoma
TW200526254A (en) 2003-09-19 2005-08-16 Novo Nordisk As Novel GLP-1 derivatives
CN1930305A (zh) 2004-01-14 2007-03-14 詹森药业有限公司 过氧化物酶体增殖物激活受体α靶基因的使用方法
EP2441466B1 (fr) 2004-04-13 2014-07-23 St Vincent's Hospital Sydney Limited Agent inhibiteur de MIC-1
EP1755649A1 (fr) 2004-04-14 2007-02-28 Medical Research Council Elimination selective de cellules cancereuses par induction d'acetyltransferase via des cytokines tnf-alpha et il-6
US8431558B2 (en) 2004-11-01 2013-04-30 The Regents Of The University Of California Compositions and methods for modification of biomolecules
US20090142338A1 (en) * 2005-03-04 2009-06-04 Curedm, Inc. Methods and Compositions for Treating Type 1 and Type 2 Diabetes Mellitus and Related Conditions
ES2381492T3 (es) 2005-04-29 2012-05-28 Glaxosmithkline Biologicals Sa Procedimiento de prevención o tratamiento de infección por M. tuberculosis
US20110319324A1 (en) 2005-05-27 2011-12-29 Five Prime Therapeutics, Inc. Methods of and compositions for stimulation of glucose uptake into muscle cells and treatment of diseases
US8673848B2 (en) 2012-01-27 2014-03-18 Novartis Ag Synthetic apelin mimetics for the treatment of heart failure
CA2632095A1 (fr) 2005-11-30 2007-06-07 Ambrilia Biopharma Inc. Promedicaments d'inhibiteurs d'aspartyl protease a base de lysine et leurs procedes de fabrication
CA2634547C (fr) 2005-12-20 2016-10-11 Bristol-Myers Squibb Company Formulations de proteine stables
CN101002945B (zh) * 2006-01-20 2012-09-05 清华大学 一种用于肿瘤治疗的新型复合物
CN101854947A (zh) 2007-08-16 2010-10-06 圣文森特医院悉尼有限公司 用于调节巨噬细胞抑制因子(mic-1)活性的药剂和方法
WO2009042798A1 (fr) 2007-09-26 2009-04-02 Cold Spring Harbor Laboratory Procédés de traitement d'une fibrose par modulation de la sénescence cellulaire
US8420088B2 (en) 2008-01-28 2013-04-16 Novartis Ag Methods and compositions using FGF23 fusion polypeptides
TW200936156A (en) 2008-01-28 2009-09-01 Novartis Ag Methods and compositions using Klotho-FGF fusion polypeptides
AU2009233429B2 (en) 2008-03-31 2014-02-13 Ferring B.V. Oxytocin analogues
KR101316159B1 (ko) 2008-10-24 2013-10-15 아이알엠 엘엘씨 생합성적으로 생성된 피롤린-카르복시-리신, 및 피롤린-카르복시-리신 및 피롤리신 잔기의 화학적 유도체화를 통한 부위 특이적 단백질 변형
WO2010052144A2 (fr) * 2008-11-05 2010-05-14 F. Hoffmann-La Roche Ag Agonistes du récepteur 2 de neuropeptide (y-2r) et leurs utilisations
EP2209003A1 (fr) 2009-01-16 2010-07-21 F. Hoffmann-Roche AG Moyens et procédés pour différencier la fibrose de la cirrhose
EP2211182A1 (fr) 2009-01-16 2010-07-28 Roche Diagnostics GmbH Procédé pour l'évaluation de la gravité de la cirrhose du foie
EP2261662B1 (fr) * 2009-06-10 2014-01-22 Forschungszentrum Borstel Leibniz-Zentrum für Medizin und Biowissenschaften Nouveaux réactifs de blocage synthétique
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
US20130053433A1 (en) 2010-01-06 2013-02-28 The University Of North Carolina At Chapel Hill Fatty acid derivatives and analogs of drugs
CN101852804B (zh) 2010-03-29 2013-06-12 中国医学科学院病原生物学研究所 Gdf15蛋白的抗体的新用途
JP5920936B2 (ja) 2010-04-27 2016-05-18 シンアフィックス ビー．ブイ． 縮合シクロオクチン化合物及び無金属クリック反応におけるそれらの使用
BR112012029611A2 (pt) 2010-05-21 2017-07-25 Merrimack Pharmaceuticals Inc proteína de fusão biespecífica, composição farmacêutica, método de tratamento de dano ao tecido em um indivíduo, método de promoção da regeração ou sobrevivência do tecido em um indivíduo e molécula de ácido nucleico
GB201018518D0 (en) * 2010-11-03 2010-12-15 Univ Leuven Kath Novel endolysin
JP5977814B2 (ja) * 2011-04-08 2016-08-24 アムジエン・インコーポレーテツド 増殖分化因子１５（ｇｄｆ−１５）を使用して代謝障害を治療または改善する方法
WO2012140647A2 (fr) 2011-04-11 2012-10-18 Yeda Research And Development Co. Ltd Sondes de liaison à l'albumine et conjugués de médicaments de celles-ci
US9394343B2 (en) 2011-07-05 2016-07-19 The Regents Of The University Of California Appetite stimulating protein
WO2013027191A1 (fr) 2011-08-25 2013-02-28 Novartis Ag Procédés et compositions utilisant des polypeptides de fusion fgf23
US9714276B2 (en) 2012-01-26 2017-07-25 Amgen Inc. Growth differentiation factor 15 (GDF-15) polypeptides
SG11201405276PA (en) 2012-02-27 2014-10-30 Amunix Operating Inc Xten conjugate compositions and methods of making same
US9550819B2 (en) 2012-03-27 2017-01-24 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
UY35144A (es) 2012-11-20 2014-06-30 Novartis Ag Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
US8921307B2 (en) 2012-11-20 2014-12-30 Novartis Ag Synthetic linear apelin mimetics for the treatment of heart failure
MX358684B (es) 2012-12-21 2018-08-31 Hoffmann La Roche Peptidos como agonistas de oxitocina.
AR094271A1 (es) 2012-12-21 2015-07-22 Aveo Pharmaceuticals Inc Anticuerpos anti-gdf15
US9161966B2 (en) 2013-01-30 2015-10-20 Ngm Biopharmaceuticals, Inc. GDF15 mutein polypeptides
JP6272907B2 (ja) 2013-01-30 2018-01-31 エヌジーエム バイオファーマシューティカルズ インコーポレイテッド 代謝障害の処置における組成物及び使用方法
RS61778B1 (sr) 2013-05-06 2021-06-30 Scholar Rock Inc Kompozicije i postupci za modulaciju faktora rasta
SG11201510618YA (en) 2013-07-03 2016-03-30 Alder Biopharmaceuticals Inc Regulation of glucose metabolism using anti-cgrp antibodies
CN105593238B (zh) 2013-07-11 2020-09-08 诺华股份有限公司 使用微生物转谷氨酰胺酶进行赖氨酸特异性化学酶法蛋白质修饰
AU2014293387B2 (en) 2013-07-25 2017-04-20 Novartis Ag Bioconjugates of synthetic apelin polypeptides
US9683018B2 (en) 2013-07-25 2017-06-20 Novartis Ag Disulfide cyclic polypeptides for the treatment of heart failure
WO2015013165A1 (fr) 2013-07-25 2015-01-29 Novartis Ag Dérivés cycliques de l'apeline pour le traitement de l'insuffisance cardiaque
KR20160031551A (ko) 2013-07-25 2016-03-22 노파르티스 아게 심부전의 치료를 위한 시클릭 폴리펩티드
NZ754961A (en) 2013-07-31 2022-04-29 Amgen Inc Growth differentiation factor 15 (gdf-15) constructs
MX2016006674A (es) 2013-11-26 2016-12-09 Novartis Ag Metodos para la conjugacion de oxima con polipeptidos modificados con cetona.
US9993494B2 (en) 2014-02-07 2018-06-12 Effector Therapeutics, Inc. Compositions and methods for treating fibrotic disease
JP6329626B2 (ja) 2014-05-01 2018-05-23 富士フイルム株式会社 赤外線センサ、近赤外線吸収組成物、感光性樹脂組成物、化合物、近赤外線吸収フィルタおよび撮像装置
WO2015171691A2 (fr) 2014-05-06 2015-11-12 Scholar Rock, Inc. Compositions et procédés de modulation de facteur de croissance
JP6721572B2 (ja) 2014-05-23 2020-07-15 ノバルティス アーゲー ジスルフィド含有タンパク質からコンジュゲートを作製するための方法
EA201790051A1 (ru) 2014-06-20 2017-04-28 Авео Фармасьютикалз, Инк. Лечение хронического заболевания почек и другого нарушения функции почек при помощи модулятора gdf15
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
ES2818109T3 (es) 2014-06-23 2021-04-09 Novartis Ag Modificaciones de proteínas específicas para un sitio
WO2015198199A1 (fr) 2014-06-23 2015-12-30 Novartis Ag Polypeptide de fusion hsa-gdf-15 et son utilisation
AU2015279525A1 (en) 2014-06-24 2016-12-15 Novo Nordisk A/S MIC-1 fusion proteins and uses thereof
JP6704358B2 (ja) 2014-07-30 2020-06-03 エヌジーエム バイオファーマシューティカルズ インコーポレイテッド 代謝障害を治療するための組成物および使用方法
EP3212213B1 (fr) 2014-10-30 2021-04-28 Acceleron Pharma Inc. Méthodes et compositions utilisant des polypeptides gdf15 pour augmenter le nombre de globules rouges sanguins
US9920118B2 (en) 2014-10-31 2018-03-20 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
WO2016102580A1 (fr) 2014-12-22 2016-06-30 Novo Nordisk A/S Protéines de fusion alpha-1-antitrypsine (a1at) et leurs utilisations
EA201791668A1 (ru) 2015-01-23 2017-11-30 Новартис Аг Синтетические конъюгаты апелина с жирной кислотой с улучшенным периодом полураспада
MA41919A (fr) 2015-04-06 2018-02-13 Acceleron Pharma Inc Hétéromultimères alk4:actriib et leurs utilisations
BR112017021510A2 (pt) 2015-04-06 2018-07-03 Acceleron Pharma Inc heteromultímeros do receptor tipo i e tipo ii da superfamília tgf-beta e sua utilização
MA53883A (fr) 2015-04-06 2021-08-18 Acceleron Pharma Inc Protéines de fusion de récepteur type i et type ii à bras unique et leurs utilisations
US20200237923A1 (en) 2015-10-14 2020-07-30 The Johns Hopkins University Protein bioconjugation method
CN108367053A (zh) 2015-12-22 2018-08-03 诺华股份有限公司 使用生长分化因子15(gdf-15)治疗或改善代谢性疾病的方法
EP3184106A1 (fr) 2015-12-23 2017-06-28 Sanofi-Aventis Deutschland GmbH Facteur de différentiation de croissance 15 en tant que biomarqueur de metformine
US11105818B2 (en) 2016-01-15 2021-08-31 Novo Nordisk A/S MIC-1 receptor and uses thereof
EP3423094A4 (fr) 2016-02-29 2019-11-06 Eli Lilly and Company Traitements impliquant le récepteur gfral
WO2017152105A1 (fr) 2016-03-04 2017-09-08 Ngm Biopharmaceuticals, Inc. Compositions et procédés pour moduler le poids corporel
KR101727506B1 (ko) 2016-07-14 2017-05-04 충남대학교 산학협력단 Gdf15 단백질 또는 이를 암호화하는 폴리뉴클레오티드를 유효성분으로 함유하는 지방간의 예방 또는 치료용 약학적 조성물
JP2020517657A (ja) 2017-04-20 2020-06-18 ノヴォ ノルディスク アー／エス アルブミン融合タンパク質の精製方法
TWI710377B (zh) 2017-05-23 2020-11-21 丹麥商諾佛 儂迪克股份有限公司 Ｍｉｃ－１化合物及其用途
JP2020533302A (ja) 2017-09-10 2020-11-19 ノヴォ ノルディスク アー／エス 肥満の治療において使用するためのｍｉｃ−１およびｇｌｐ−１
EP3934679A1 (fr) 2019-03-08 2022-01-12 Amgen Inc. Polythérapie par facteur de différenciation de croissance 15
WO2021067655A1 (fr) 2019-10-04 2021-04-08 Amgen Inc. Utilisation de gdf15 pour le traitement d'un syndrome cardiométabolique et d'autres affections
CN115260313B (zh) 2019-12-31 2023-07-18 北京质肽生物医药科技有限公司 Glp-1和gdf15的融合蛋白以及其缀合物
AU2021254751A1 (en) 2020-04-15 2022-11-17 Theradaptive, Inc. Compositions and methods for targeted therapeutic delivery to bone
WO2022092915A1 (fr) 2020-10-30 2022-05-05 가톨릭대학교 산학협력단 Composition destinée à la prévention et au traitement de maladies immunitaires contenant du gdf15 en tant que principe actif

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014083505A1 (fr) * 2012-11-30 2014-06-05 Novartis Ag Procédés pour la fabrication de conjugués à partir de protéines contenant du disulfure

Also Published As

Publication number Publication date
ECSP17004665A (es) 2018-11-30
PT3157571T (pt) 2022-02-14
WO2015200078A8 (fr) 2016-04-14
TW201613653A (en) 2016-04-16
US10588980B2 (en) 2020-03-17
MX2016017395A (es) 2017-05-01
CN114133443A (zh) 2022-03-04
IL248990B (en) 2019-09-26
KR20230056796A (ko) 2023-04-27
US10786576B2 (en) 2020-09-29
JP2017519024A (ja) 2017-07-13
IL248990A0 (en) 2017-01-31
TWI701048B (zh) 2020-08-11
US20160030585A1 (en) 2016-02-04
TWI750725B (zh) 2021-12-21
SG10201912965TA (en) 2020-02-27
CL2016003281A1 (es) 2017-06-09
TW202204384A (zh) 2022-02-01
US20240066132A1 (en) 2024-02-29
AU2015280351A1 (en) 2016-12-08
DK3157571T3 (da) 2022-02-21
CN114099693A (zh) 2022-03-01
SI3157571T1 (sl) 2022-04-29
US20210000964A1 (en) 2021-01-07
CA2953480A1 (fr) 2015-12-30
MX367520B (es) 2019-08-26
CU24455B1 (es) 2019-11-04
TN2016000558A1 (en) 2018-04-04
EA039074B1 (ru) 2021-11-30
PH12016502294A1 (en) 2017-02-13
AU2015280351B2 (en) 2018-07-05
EP3157571A1 (fr) 2017-04-26
PE20171095A1 (es) 2017-08-07
CY1125006T1 (el) 2023-01-05
AU2015280351C1 (en) 2022-11-24
JP7051959B2 (ja) 2022-04-11
CR20160596A (es) 2017-05-08
PH12016502294B1 (en) 2017-02-13
BR112016028884A2 (pt) 2017-10-31
ES2905479T3 (es) 2022-04-08
JP2023099133A (ja) 2023-07-11
JP6636959B2 (ja) 2020-01-29
JO3813B1 (ar) 2021-01-31
JP2022095757A (ja) 2022-06-28
HUE057845T2 (hu) 2022-06-28
MA40278A (fr) 2017-04-26
US11752211B2 (en) 2023-09-12
EP3988170A1 (fr) 2022-04-27
JP2019206563A (ja) 2019-12-05
HK1232160A1 (zh) 2018-01-05
LT3157571T (lt) 2022-02-25
KR102559975B1 (ko) 2023-07-27
CU20160189A7 (es) 2017-04-05
EP3157571B1 (fr) 2021-11-24
TW202039004A (zh) 2020-11-01
EA201692466A1 (ru) 2017-04-28
KR20170020878A (ko) 2017-02-24
MY193993A (en) 2022-11-07
UY36186A (es) 2016-01-29
CN107073130B (zh) 2021-11-16
JP6823696B2 (ja) 2021-02-03
PL3157571T3 (pl) 2022-03-28
SG11201609704TA (en) 2017-01-27
US20180326079A1 (en) 2018-11-15
AP2016009585A0 (en) 2016-11-30
GT201600263A (es) 2019-07-19
JP2020203934A (ja) 2020-12-24
RS62907B1 (sr) 2022-03-31
HRP20220152T1 (hr) 2022-04-15
CN107073130A (zh) 2017-08-18
WO2015200078A1 (fr) 2015-12-30

Similar Documents

Publication Publication Date Title
TWI792596B (zh) 新穎脂肪酸及其於共軛至生物分子之用途
ES2963839T3 (es) Polipéptidos de relaxina modificados que comprenden un potenciador farmacocinético y usos de los mismos
CA3014641C (fr) Agonistes partiels du recepteur de l'insuline
KR102310392B1 (ko) 글루카곤-ｇｌｐ-1-ｇｉｐ 삼원 효능제 화합물
BRPI0607248A2 (pt) conjugado de um polipeptìdeo e um oligossacarìdeo, composição farmacêutica, uso do conjugado, e, processo para a preparação de um conjugado
KR20080016674A (ko) 트랜스글루타미나제 매개 성장 호르몬 컨쥬게이션
ES2349743T3 (es) Derivados de la il-21.
KR20100014215A (ko) 신규 단백질 접합체 및 그것의 제조 방법
US20180009849A1 (en) Ghrelin analogues
EP1673387B1 (fr) Derives de il-21
JP2008531482A (ja) Ｃ末端がｐｅｇ化された成長ホルモン
BR112016028884B1 (pt) Conjugado compreendendo uma biomolécula ligada a um ácido graxo, seu uso, mistura, combinação, composição farmacêutica, e composto
MXPA06004059A (en) Il-21 derivatives